IRON: Disc Medicine, Inc. Price/Earnings to Growth Ratio

Negative cash flow resulting from a lack of finished products drives the current price action, which is confirmed by the PEG growth stock filter. The 0.00 value represents a fresh level, indicating potential undervaluation. The foundation of Disc Medicine, Inc. (IRON) lies in its cutting-edge developments in anemia therapy, while strong management effectively raises capital to push drugs toward the final stages of approval.

Disc Medicine, Inc. - IRON Price/Earnings to Growth Ratio (period 04/28/2023 - 11/14/2026)

Analytical breakdowns for Disc Medicine, Inc. (IRON)

- share price and consensus valuation forecast:

Price Performance Chart Disc Medicine Inc|IRON - Analyst Consensus Forecast

- market capitalization information:

Market Value Disc Medicine Corp|IRON - Total Company Value

- issuer book value statistics:

Net Assets per Single Share Disc Medicine|IRON - Company Book Value|Market-to-Book Ratio discmedicine.com|IRON - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

IRON - Net Profit|Future Profit Disc Medicine, Inc.|IRON - Price to Earnings Ratio|Future Price to Earnings Multiple Disc Medicine Pharma|IRON - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Disc Medicine Corp|IRON - Operating profit EBITDA|Net earnings per one share for the last twelve months Disc Medicine|IRON - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months discmedicine.com|IRON - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Disc Medicine, Inc.

- total revenue and sales volume data:

IRON - Revenue and Sales Volume|Company Future Sales Volume Disc Medicine Inc|IRON - P/S Multiple|Market Cap to Expected Sales Ratio Disc Medicine Corp

General company analysis:Disc Medicine Inc (IRON)

Mass-produced product of Disc Medicine Inc

The prospects of Disc Medicine, Inc. (IRON) in hematology and the development of bitopertin are directly reflected in the dynamics of the estimated PEG ratio. This coefficient compares the current P/E to earnings growth rates: a value below one signals that the asset is undervalued relative to its expansion, although an extreme discount may indicate market concerns regarding the fundamental quality of the biopharmaceutical assets.

Competing companies